| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5529791 | BAUSCH | Extended release form of diltiazem |
Jun, 2013
(10 years ago) | |
| US7108866 | BAUSCH | Chronotherapeutic diltiazem formulations and the administration thereof |
Dec, 2019
(4 years ago) | |
| US6923984 | BAUSCH | Cushioning wax beads for making solid shaped articles |
Feb, 2021
(3 years ago) | |
Cardizem La is owned by Bausch.
Cardizem La contains Diltiazem Hydrochloride.
Cardizem La has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Cardizem La are:
- US5529791
- US7108866
- US6923984
Cardizem La was authorised for market use on 06 February, 2003.
Cardizem La is available in tablet, extended release;oral dosage forms.
Cardizem La can be used as treatment of hypertension and angina pectoris.
The generics of Cardizem La are possible to be released after 25 February, 2021.
Drugs and Companies using DILTIAZEM HYDROCHLORIDE ingredient
Market Authorisation Date: 06 February, 2003
Treatment: Treatment of hypertension and angina pectoris
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of CARDIZEM LA before it's drug patent expiration?
More Information on Dosage
CARDIZEM LA family patents
